semaglutide clinic seattle Ideal Protein West Eastside Weight and Wellness, NOW Seattle Weight Loss & Wellness

[1] GLP-1/GIP agents such as tirzepatide are not currently listed as disqualifying by major US blood organizations

Semaglutide trials (STEP program) reported nausea in approximately 25-35% of participants at therapeutic doses

Those conditions include rapid dose escalation of bupropion, concurrent use of medications that lower the seizure threshold, eating disorders with purging behavior, alcohol withdrawal, and critically for our discussion, dehydration and electrolyte imbalances

It is a complex, chronic disease influenced by biology, environment, stress, trauma, and access to care

You are granted unlimited access to our patient care team and providers for ongoing support